<DOC>
	<DOCNO>NCT02061215</DOCNO>
	<brief_summary>Using novel CYTOF technology measure wide array innate adaptive cell proportion cytokine level , plan pilot study old ( &gt; /=60 year ) young ( 20-40 year ) renal transplant recipient CMV seropositive ( regardless donor serology ) . Viral load measurement perform baseline prior transplant ( within 1 week ) , 3 , 7 10 month transplant . It expect patient receive anti-CMV prophylaxis 6 month post-transplant , latter two time point reflect responses `` release '' antiviral suppression . Each patient serve control , comparison make measurement baseline timepoint . Blood 10 patient age group study , collect virologic immune response data : - CYTOF ( broad array measurement ) - Tetramer assay ( require recipient HLA type A1 , A2 , B7 ) - CMV viral load PCR - Response pneumococcal antigen inactivate influenza virus In addition , clinical data collect time point indicate , particularly renal function presence/absence acute rejection .</brief_summary>
	<brief_title>Study CMV Kidney Transplant Recipients</brief_title>
	<detailed_description />
	<criteria>1 . Adults young age 2040 year old &gt; /= 60 year 2 . Anticipate renal transplant within 2 week 3 . CMV seropositive renal transplant recipients 4 . HLA type A1 , A2 , B7 recipient 1 . Pediatric recipient 2 . Multiorgan transplant recipient 3 . Highly sensitize ( antigen level ) recipients 4 . Prior organ transplant recipient 5 . Patients wish participate study , consent research 6 . Patients active CMV infection 7 . Seronegative 8 . HLA Type organ recipient correspond A1 , A2 , B7</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>CYTOF</keyword>
	<keyword>CMV</keyword>
	<keyword>PCR</keyword>
	<keyword>HLA</keyword>
</DOC>